Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America

Summary

This observational, retrospective study aims to understand the treatment patterns and outcomes of patients with pulmonary and extra-pulmonary neuroendocrine carcinomas (NEC) in Latin America (Brazil, Mexico, Argentina, and Peru). The research will collect data from medical records to analyze factors like patient demographics, diagnosis methods, tumor characteristics, treatment approaches, and disease progression. The study is non-interventional, meaning patient care will follow standard clinical practice, with data gathered via an electronic system.

Eligibility

Inclusion Criteria:

* ≥18 years old
* Diagnosed between August 2014 and August 2024 with one of the following:
* Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
* Large-cell neuroendocrine carcinoma (LCNEC) or mixed
* Small Cell Lung Cancer (SCLC) or mixed
* Adequate and accessible medical records for data collection
* Tumor block collected from 2014 onwards

Exclusion Criteria:

* Patients with active, concurrent malignancies at the time of NEC diagnosis, except for non-invasive cancers like basal cell carcinoma or squamous cell carcinoma of the skin, or in situ cervical cancer.
* Patients or their legal representatives unwilling or unable to provide informed consent (if needed per ethics committee).

Conditions4

Browse More Trials